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Abstract 
Background: Thailand is aiming to eliminate malaria by the year 2024. Plasmodium vivax has now become the 
dominant species causing malaria within the country, and a high proportion of infections are asymptomatic. A bet‑
ter understanding of antibody dynamics to P. vivax antigens in a low‑transmission setting, where acquired immune 
responses are poorly characterized, will be pivotal for developing new strategies for elimination, such as improved 
surveillance methods and vaccines. The objective of this study was to characterize total IgG antibody levels to 11 key 
P. vivax proteins in a village of western Thailand.
Methods: Plasma samples from 546 volunteers enrolled in a cross‑sectional survey conducted in 2012 in Kan‑
chanaburi Province were utilized. Total IgG levels to 11 different proteins known or predicted to be involved in reticu‑
locyte binding or invasion (ARP, GAMA, P41, P12, PVX_081550, and five members of the PvRBP family), as well as the 
leading pre‑erythrocytic vaccine candidate (CSP) were measured using a multiplexed bead‑based assay. Associations 
between IgG levels and infection status, age, and spatial location were explored.
Results: Individuals from a low‑transmission region of western Thailand reacted to all 11 P. vivax recombinant pro‑
teins. Significantly greater IgG levels were observed in the presence of a current P. vivax infection, despite all infected 
individuals being asymptomatic. IgG levels were also higher in adults (18 years and older) than in children. For most 
of the proteins, higher IgG levels were observed in individuals living closer to the Myanmar border and further away 
from local health services.
Conclusions: Robust IgG responses were observed to most proteins and IgG levels correlated with surrogates of 
exposure, suggesting these antigens may serve as potential biomarkers of exposure, immunity, or both.
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Background
Thailand is a region of low malaria transmission, with 
approximately 52,000 (16,000–150,000) cases esti-
mated in 2015 [1]. The country is currently within the 
‘control’ phase per the World Health Organization, and 
the National Malaria Strategy proposes to eliminate 
malaria by the year 2024 (Department of Disease Con-
trol, Ministry of Public Health, Thailand). This is part of 
a wider goal of a malaria-free Asia–Pacific by the year 
2030, declared at the 9th East Asia Summit in 2014 by the 
Asia–Pacific Leaders Malaria Alliance. As malaria trans-
mission has decreased in Thailand, Plasmodium vivax 
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has become the dominant and more stable malaria para-
site species [2, 3], as has been reported in other regions of 
the world where P. vivax and Plasmodium falciparum are 
sympatric [4–6]. Hence, a renewed and sustained effort 
will be required to eliminate P. vivax. A greater under-
standing of the antibody dynamics to P. vivax in this low-
transmission region will be essential for developing and 
implementing key elimination tools, such as vaccines and 
improved surveillance methods [7].
Following P. vivax infections in Thai patients, IgG 
responses are induced to a number of different P. vivax 
antigens [8–11], despite the relatively low transmission of 
P. vivax in this region. Two studies provide evidence that 
IgG responses to both pre-erythrocytic and blood-stage 
P. vivax antigens can be maintained for at least 1 year in 
the absence of detectable blood-stage infections, sug-
gesting acquisition of immunity [12, 13]. Whilst these 
previous studies have established that IgG responses do 
develop following P. vivax infections in Thailand, and 
that these responses can be long-lasting, there is still a 
paucity of information concerning IgG responses on a 
community-wide level encompassing all age groups in 
low transmission settings.
In this study, IgG levels were measured against sev-
eral P. vivax antigens within a comprehensive group of 
volunteers, using plasma samples from a cross-sectional 
survey conducted in western Thailand in 2012. The pro-
teins assessed included PVX_081550 (a putative StAR-
related lipid transfer protein), the putative GPI-anchored 
micronemal antigen (GAMA), P12, P41, the asparagine-
rich protein (ARP), five members of the reticulocyte 
binding protein (RBP) family and the circumsporozo-
ite protein (CSP). PVX_081550, GAMA, P12, P41, and 
ARP are all potential blood-stage vaccine candidates 
based on their P. falciparum orthologs which are known 
or predicted to be involved in erythrocyte invasion [14–
17]. The RBP family is thought to be responsible for the 
restricted host cell selectivity of P. vivax, making these 
antigens potential targets for a vaccine that interrupts 
blood-stage infections [18, 19]. CSP is a well-studied 
pre-erythrocytic candidate; the P. falciparum orthologue 
is the major component of the RTS,S vaccine [20]. The 
association of IgG levels with asymptomatic P. vivax 
infections, age, and spatial location were all explored, and 
how this information can contribute to the development 
of new or improved tools to facilitate elimination of P. 
vivax from western Thailand is discussed.
Methods
Cross‑sectional survey
The cross-sectional survey was conducted in Kan-
chanaburi and Ratchaburi Provinces of western Thailand 
in September 2012 (Nguitragool et al. submitted). Briefly, 
4309 volunteers were surveyed in eight villages, where 
P. vivax infection prevalence varied from 1.45 to 7.4%. 
Prevalence was defined by a positive quantitative PCR 
(known as qMAL), with species identification by single-
plex qPCR, both as described [21, 22]. From all partici-
pants, 250 μl of capillary blood were collected by finger 
prick into an EDTA-containing microtainer. A 50 μl por-
tion was immediately preserved for RNA extraction on-
site, whilst the remaining blood was separated into pellet 
(for DNA extraction) and plasma on the same day and 
stored at −20 and −80 °C, respectively.
The ‘Bongti moo 3’ village was identified as having one 
of the higher rates of malaria prevalence amongst the eight 
villages surveyed (4.1%): thus samples collected from 546 
volunteers living in this village were selected for IgG anal-
ysis in this study. Of those, 22 volunteers had confirmed 
P. vivax infections by qPCR at the time of sampling, as 
detailed in Table  1. All 22 infections were considered 
asymptomatic. We defined asymptomatic individuals as 
having no fever at the time of blood collection (<37.5 °C), 
in addition to no history of fever or any other malaria 
symptoms (feeling ‘unwell’) within the previous 2  days. 
Temperature was measured with an infrared thermom-
eter prior to blood collection. As individuals were not 
seen again after this time, we do not know whether they 
subsequently developed febrile symptoms, a limitation of 
our definition of asymptomatic individuals. The feature 
of asymptomatic infections reflected the total cross-sec-
tional survey, where 91.7% of P. vivax infections were clas-
sified as asymptomatic (Nguitragool et al. pers. Comm.). 
Age of the volunteers ranged from 6 months to 87 years, 
and 47% were male. Other demographic and epidemio-
logical variables are shown in Table 1.
The location of each volunteer’s home was recorded 
by GPS. Based on the distance from the Myanmar bor-
der, each volunteer was assigned to either group 1 (liv-
ing close to the border) or 2 (away from the border and 
closer to the local school, malaria clinic, and other health 
facilities, Fig. 1).
Protein selection and production
IgG responses were measured to 11 different P. 
vivax protein constructs: the full-length ectodo-
mains of PVX_081550, GAMA (PVX_088910), 
P12 (PVX_113775), P41 (PVX_000995), and ARP 
(PVX_090210) [23]; CSP (based on a Korean isolate [24]); 
and five members of the RBP family (RBP1a, RBP2a, 
RBP2c, RBP2-P2, and RBP1b) [18]. For RBP2c, the frag-
ment does not include the erythrocyte-binding domain, 
which encompasses residues 128–429, and is therefore 
referred to as RBP2cNB [25].
Proteins were expressed and purified using hexa-histi-
dine tags in three collaborating laboratories as previously 
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described, using HEK293E [26] or Escherichia coli [18, 
19, 27] expression systems. PVX_081550, GAMA, P12, 
P41, and ARP also contained a Cd4 tag to assess protein 
expression levels [26].
Antibody measurements
IgG levels were measured using a multiplexed bead-
based assay as previously described [26]. Briefly, 
2.5  ×  106 COOH microspheres (Luminex Corp) were 
incubated for 20  min at room temperature in 100  mM 
monobasic sodium phosphate (pH 6.2); 50  mg/ml 
sulfo-NHS (N-hydroxysulfosuccinimide sodium salt) 
was added to convert the protein’s carboxyl groups to 
amine-reactive NHS esters and 50 mg/ml of EDC [N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydro-
chloride] used to cross-link P. vivax proteins to the 
microspheres, with incubation at 4 °C overnight. Optimal 
protein concentrations were determined experimentally 
to generate a log-linear standard curve with a positive 
control plasma pool prepared from immune Papua New 
Guinean (PNG) donors (see below). This enabled all 
plasma samples to be tested at one dilution with all pro-
teins multiplexed.
50  μl of protein-conjugated microspheres in buffer 
were added to a 96-well V bottom tissue-culture plate 
(500 microspheres per well) and incubated with 50 μl of 
test plasma at a 1/100 dilution for 30 min at room tem-
perature on a plate shaker. All dilutions were made in 
phosphate buffered saline containing 1% bovine serum 
albumin and 0.05% (v/v) Tween-20 (denoted as PBT), and 
all samples were run singularly. Following the incuba-
tion, the plate was centrifuged at 600×g for 3 min and the 
microspheres washed three times with 100 μl of PBT. The 
washed microspheres were incubated for 15  min with 
1/100 detector antibody, PE-conjugated anti-human IgG 
Fc (1  mg/ml, Jackson ImmunoResearch), at room tem-
perature on a plate shaker. The microspheres were then 
washed and assayed on a Bio-Plex  200® and the results 
expressed as the median fluorescent intensity (MFI).
On each plate, a twofold serial dilution from 1/50 to 
1/25,600 of a positive control plasma pool (generated 
from PNG adults) was included to generate a standard 
curve to allow standardization between plates. If the 
standard curve failed on a plate, the results for that pro-
tein were excluded. If less than 15 beads were counted for 
a bead region of a well, the result for that plasma sample 
was excluded.
Statistical analysis
The raw MFI results were converted to relative anti-
body units using protein-specific standard curve data. 
A log–log model was used to obtain a more linear rela-
tionship, and a five-parameter logistic function was 
used to obtain an equivalent dilution value compared to 
the PNG control plasma [ranging from 1.95 × 10−5 (or 
1/51,200) to 0.02 (or 1/50)] [26]. The interpolation was 
performed in R.
Table 1 Characteristics of  the 546 cross-sectional survey 
volunteers
a Demographic/epidemiological details were not recorded for all 546 
volunteers: numbers as shown
Variable Value
Plasmodium infection, number (%) 35 (6.4%)
 P. vivax 20
 P. falciparum 5
 Mixed P. vivax/P. falciparum 2
 Undetermined 8
Age (years), median (range)a 22 (0.5–87)
 0–6 years, number 89
 7–12 years, number 107
 13–17 years, number 48
 18 years and older, number 298
Gender, number (%)a
 Male 254 (46.7%)
 Female 289 (53.3%)
GPS location, number (%)
 Group 1 (close to Myanmar) 80 (14.7%)
 Group 2 (close to local facilities) 466 (85.3%)
Length of time in Thailand, number (%)a
 More than 2 months 537 (100%)
Slept outside village last month, number (%)a
 Yes 2 (0.4%)
 No 534 (99.6%)
Anti‑malarial drugs taken in last 2 months, number (%)a
 Yes 4 (0.7%)
 No 532 (99.3%)
Taking current medications, number (%)a
 Yes 5 (0.9%)
 No 531 (99.1%)
Bed net used last night, number (%)a
 Yes 529 (98.7%)
 No 7 (1.3%)
How long house has had bed net, number (%)a
 Past 6 months 66 (12.4%)
 1 year or more 1 (0.2%)
 2 years or more 464 (87.4%)
Feeling unwell today, number (%)a
 Yes 3 (0.6%)
 No 533 (99.4%)
Fever last 2 days, number (%)a
 Yes 2 (0.4%)
 No 534 (99.6%)
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Five of the proteins contained Cd4 tags [26]. As 
such tags are known to induce an antibody response 
in some individuals [28], the measured antibody level 
 (Abmeas) was assumed to be a combination of the true 
antibody response to the protein  (Abtrue) and the anti-
body response to the Cd4 tag  (AbCd4tag): log(Abmeas) = lo
g(Abtrue) − βlog(AbCd4tag). The slope of the curve (β) was 
estimated using linear regression, and  Abtrue was then 
Fig. 1 Location of houses of the study families in Bongti moo 3. Group 1 (n = 80) contains houses that lie closer to the border with Myanmar, and 
group 2 (n = 466) contains houses that are closer to the local health facilities and schools
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estimated as the antibody response that would be meas-
ured when the Cd4 response is at the lowest measured 
value (1.95 × 10−5) [26].
Using the interpolated and Cd4-transformed data, 
further analysis and data presentation was performed 
in Prism version 6 (GraphPad, USA) or Stata ver-
sion 12.1 (StataCorp, USA). Antibody values were 
 log10-transformed and differences in IgG levels between 
categorical exposure variables determined using unpaired 
two-sample t tests or ANOVA with Sidak’s multiple-com-
parisons test. A multivariate linear regression model was 
used to determine the most significant associations with 
antibody level. The significance threshold was p = 0.05. 
Data are presented using box-plots (median), with error 
bars showing the 5–95 percentile and dot points the out-
liers. All antibody data generated (relative antibody units, 
not  log10-transformed) are provided in Additional file 1, 
along with the appropriate epidemiological data.
Mathematical methods
Cross-sectional data on age-specific seropositivity to 
P. vivax antigens are assumed to represent cumulative 
exposure of the population to P. vivax, allowing estima-
tion of exposure patterns. Seropositivity was set at the 
mean plus two times the standard deviation of uninfected 
individuals aged 2–3 years from the study (young enough 
to have had limited exposure but old enough to no longer 
have maternally-acquired antibodies [13]). Two different 
models for describing seroprevalence curves were com-
pared [29]. Model 1 assumes that the seroconversion 
rate is constant over time (i.e., exposure is constant over 
time). The seroconversion rate is λ and the seroreversion 
rate is ρ. The predicted proportion of individuals of age a 
that is seropositive is given by:
In Model 2, the assumption was a stepwise reduction in 
transmission tc years ago. Before reduction, it is assumed 
the seroconversion rate was λ0, and that it drops to λc. 
The proportional reduction is denoted to be γ  =  λc/λ0. 
Again, the seroreversion rate is ρ. The proportion of indi-
viduals of age a that is seropositive is given by the follow-
ing formula from Yman et al. [29].
The likelihood that the model fits the data was calcu-
lated using a binomial distribution. The models were fit-
ted in a Bayesian framework using Markov Chain Monte 
Carlo methods with uninformative uniform priors. 
P(a) =

+ ρ
(
1− e
−(+ρ)a
)
P(a) =
{
c
c+ρ
(
1− e
−(c+ρ)a
)
a ≤ tc
c
c+ρ
+
(0−c)ρ
(0+ρ)(c+ρ)
e
−(c+ρ)tc −
0
(0+ρ)
e
−(c+ρ)ae
−(0−c)(a−tc) a > tc
Posterior median parameter estimates and 95% credible 
intervals are presented in Additional file 2.
Results
Multiple Plasmodium vivax proteins are immunogenic 
in western Thailand
IgG levels to the 11 P. vivax proteins were first analysed 
in all 546 samples collected in Bongti moo 3. Overall, 
IgG levels were lower in comparison to positive con-
trol immune plasma pooled from PNG adults (Fig.  2). 
Despite the overall lower levels, a proportion of volun-
teers had relatively high IgG levels, with some reaching 
(or exceeding) levels equivalent to a 1/50 dilution of the 
pooled plasma from PNG adults. Whilst the antibody 
levels cannot be directly compared between the differ-
ent proteins, a higher proportion of volunteers reached 
the equivalent of a 1/100 dilution of the positive control 
plasma against the RBPs and CSP (3.5–5.7%), compared 
to the other four blood-stage proteins (0–0.6%). For 
these four blood-stage proteins, correction for the Cd4 
tag will have resulted in slightly lower estimates of anti-
body units. IgG levels between the five RBPs tested were 
significantly correlated (pairwise correlation coefficients 
of 0.35–0.76, all p < 0.05 after Sidak’s multiple-compari-
sons correction).
IgG levels are higher in individuals with a current 
Plasmodium vivax infection
IgG levels were next compared between individuals who 
had a current P. vivax infection and those who did not. 
Despite the fact that infected individuals were asympto-
matic (and hence had a low parasite density, 0.125–444 
copies P. vivax 18S gene/μl), they had significantly higher 
IgG levels to nine of 11 P. vivax proteins (t test, p = 0.018 
to <0.0001) (Fig.  3a). One exception was the pre-eryth-
rocytic antigen CSP; whilst there was a trend towards 
higher IgG levels in volunteers with a current infection, 
this did not reach statistical significance (p = 0.09). Even 
in the currently-uninfected volunteers, there was a pro-
portion that had exceptionally high IgG levels against 
CSP detected, equal to or exceeding 1/100 and 1/50 dilu-
tions of the immune pool from PNG. The other exception 
was for the blood-stage protein ARP. In this case, the IgG 
levels were remarkably similar between the two groups, 
with less variation in levels compared to the other pro-
teins (Fig. 3a). As seen for CSP, in the group of P. vivax-
uninfected volunteers there were some exceptionally 
high IgG levels detected against the RBP proteins, again 
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equaling or exceeding that observed in the immune PNG 
control pool.
IgG levels increase with age
The association of IgG level with age was next assessed. 
For 33 volunteers the age was recorded as a bracket (i.e., 
0–6 years, 7–12 years, 13–17 years, 18 years and older), 
and hence association of antibodies with age was con-
ducted by comparing these defined age groups. For nine 
of the 11 P. vivax proteins, IgG levels were significantly 
higher in adults aged 18  years and older compared to 
those in the two groups of younger children (0–6  years 
and 7–12  years, p  <  0.0001) (Fig.  3b). For multiple pro-
teins this difference was also evident compared to older 
children aged 13–17  years (PVX_081550, GAMA, P12, 
P41, CSP, RBP1a, and RBP2cNB, p  <  0.0001). For P41 
and CSP, there was also a significant difference between 
young children 0–6  years and older children aged 
13–17  years (p  =  0.003 and p  =  0.018, respectively). 
For these nine antigens where an association with age 
was clear, there were no exceptionally high IgG lev-
els detected in the youngest age group of children. For 
RBP2-P2 and RBP1b, there was no significant associa-
tion with age (Fig. 3b). For these two proteins, IgG levels 
were very similar between the four defined age groups, 
and in addition high IgG levels were detected in even the 
youngest group of children aged 0–6  years. For the 509 
volunteers where an exact age was recorded, there was a 
statistically significant correlation between age and IgG 
level to the same nine of 11 proteins (Spearman r cor-
relation coefficients of 0.25–0.65, n  =  389–509). There 
was a weak but significant correlation for RBP1b (r = 0.1, 
p = 0.02, n = 509).
Age-dependent trends in the proportion of seroposi-
tive individuals were also analysed using reversible sero-
catalytic models [29, 30], for the nine proteins where an 
association with age was evident. There was a step change 
in the seropositive proportion between the ages of 15 and 
30 (Fig. 4), with Model 2 providing the better fit for most 
proteins. This suggests either a reduction in transmission 
15–30 years ago, or an age-dependent change in exposure 
patterns, for example due to increased exposure to mos-
quito bites during the ages of 15–30 years due to changing 
work patterns. The results from the serocatalytic models 
also indicate long-lived IgG responses, with half-lives of 
more than 20 years for most antigens (Additional file 2).
IgG levels can reflect spatial heterogeneity
Given the interest in using antibody levels for surveillance 
[31], spatial heterogeneity in IgG levels was assessed. As 
volunteers all came from one village and lived within 
3 km of each other, a crude distinction was made based 
on ease of reaching the volunteer’s home. Group 1 vol-
unteers lived closer to the Myanmar border and further 
from local health facilities, whilst group 2 volunteers 
lived further from the border and closer to these facilities 
(Fig.  1). Significant levels of spatial heterogeneity were 
observed in IgG levels to seven of the 11 P. vivax protein 
constructs tested (Fig.  3c); IgG levels to PVX_081550, 
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Fig. 2 IgG levels to 11 Plasmodium vivax proteins in Thai volunteers. 
Relative antibody units, as compared to the immune control plasma 
pool, for each protein were calculated for everyone (n = 315–546). 
Box plots represent the median and interquartile range of 
 log10‑transformed data, error bars show the 5–95 percentile and filled 
circles show outlier values. The 1/50 and 1/100 values of the immune 
control plasma pool are shown in black and blue lines, respectively
(See figure on next page.) 
Fig. 3 IgG levels to 11 Plasmodium vivax proteins in relation to other variables. a The Thai volunteers were divided into P. vivax‑negative (n = 299–
524) and P. vivax‑positive (n = 16–22) to determine associations of IgG levels with current infection. Statistical difference between the two groups 
was assessed using the Student’s t test. The 1/50 and 1/100 values of the immune control plasma pool are shown in black and blue lines, respectively. 
b The volunteers were divided into four age groups, 0–6 years (n = 56–89), 7–12 years (n = 58–107), 13–17 years (n = 32–48) and 18 years and older 
(n = 166–298), to determine associations of IgG levels with age. Statistical difference between age groups was assessed using a one‑way ANOVA 
with Sidak’s multiple‑comparisons test. c The volunteers were divided into two spatial groups (see Fig. 1): those living near the border, group 1 
(n = 54–80), and those living near health facilities, group 2 (n = 261–466), to determine associations of IgG levels with spatial heterogeneity. Statisti‑
cal difference between the two groups was assessed using the Student’s t test. In all panels, box-plots represent the median and interquartile range, 
error bars show the 5–95 percentile and filled circles show outlier values. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05
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GAMA, P12, P41, CSP, RBP1a, and RBP2cNB were 
significantly higher in group 1 than in group 2 (t test, 
p =  0.047 to <  0.0001). There was no significant differ-
ence in IgG level between the two spatial groups for ARP, 
RBP2a, RBP2-P2 and RBP1b, which includes the antigens 
for which there was no age association, suggesting that 
exposure may have limited effect on immune responses 
to these antigens.
Other demographic and epidemiological factors were 
also explored in relation to the antibody response, where 
there were a significant number of people in two or more 
different groups (see Table 1). For most P. vivax proteins 
there was no statistically significant difference in IgG 
level between males and females, except for RBP1a where 
males had slightly higher IgG levels (n = 542, p = 0.028, 
t test). An association was also evident for RBP1a with 
bed net ownership; IgG levels were significantly higher 
in individuals who had owned a bed net only for the 
past 6  months, compared to those who had owned one 
for more than 2  years (n =  530, p =  0.03). No associa-
tion with bed net ownership was observed for the other 
ten proteins, suggesting the association between anti-
RBP1a antibodies and bed net ownership may have been 
a chance occurrence.
Age and current Plasmodium vivax infection are the best 
predictors of IgG level
Finally, the best predictors of antibody level were 
explored using a multivariate linear regression model. 
For each protein, any variables that had a significant 
association with antibody level were initially included 
in the model. A backward, stepwise, elimination process 
was used to determine the final best-fit model, with vari-
ables that were not significant when adjusted removed 
(Table  2). Age was assessed as both a linear and quad-
ratic term, with the assumption that antibody levels first 
increase with age but that this reaches a plateau. For most 
proteins where there was a significant association with 
Fig. 4 Serocatalytic models fitted to cross‑sectional data on age‑dependent seropositivity for nine Plasmodium vivax antigens. Black squares denote 
the proportion of seropositive individuals and vertical bars denote the 95% confidence interval. Model 1 (blue) assumes a constant seroconversion 
rate over time. Model 2 (green) assumes a stepwise reduction in seroconversion rate
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age, this was true for both the linear and quadratic terms 
in the final model. For nearly all proteins, age and current 
P. vivax infection remained significantly associated with 
antibody level. For CSP, only age remained significantly 
associated (spatial location was univariately associated). 
For GAMA, only age and spatial location remained sig-
nificantly associated. For ARP, only age was significantly 
associated univariately, and for RBP2-P2 only current P. 
vivax infection was significantly associated univariately. 
For RBP1a, sex and bed net usage, in addition to age and 
current P. vivax infection, remained significantly associ-
ated. For PVX_081550, P12, and RBP2cNB, spatial loca-
tion, in addition to age and current P. vivax infection, 
remained significantly associated.
Discussion
In this study, it was observed that IgG antibodies to mul-
tiple P. vivax proteins are acquired in individuals living 
in an endemic region of western Thailand, despite the 
overall low transmission. The level of IgG observed var-
ied greatly amongst volunteers of this cross-sectional 
survey. In some individuals, IgG levels were equivalent to 
the immune control plasma pool made from PNG adults, 
whilst in others no protein-specific IgG was detected. Ten 
of 11 P. vivax proteins tested are expressed during the 
blood-stage of the parasite’s lifecycle, and it is likely their 
proposed location on the surface of merozoites makes 
them immunogenic targets [14, 32, 33]. PVX_081550 is 
an exception, as the P. falciparum orthologue of this pro-
tein locates to the parasitophorous vacuole, although 
there is some evidence it may be transferred into the api-
cal organelles of merozoites [34]. The CSP protein locates 
to the surface of the sporozoite, and is well described as 
being immunogenic [34]. Recent results using samples 
from the same region of western Thailand demonstrated 
that RBP1b was poorly immunogenic in symptomatic 
P. vivax patients [18]. The current results show that 
this protein is immunogenic in asymptomatic P. vivax 
patients, and hence further research should investigate a 
potential link between IgG levels to RBP1b and associa-
tion with protection from clinical malaria in this region.
Of the 546 volunteers included in this study, the 
majority was not infected with P. vivax (nor any other 
Plasmodium spp.) during the time of blood collection. 
Despite this, and considering the overall low transmis-
sion in the region, many volunteers had detectable IgG 
levels. The results from the serocatalytic model are con-
sistent with IgG antibody responses being relatively long 
lived. Whilst this is likely the case, as the data were from 
a cross-sectional survey the relative longevity of the 
observed IgG antibodies cannot be concluded. Further 
studies utilizing samples from longitudinal surveys will 
be required, as has recently been done for CSP [13]. As 
these previous results indicated CSP is able to induce 
long-lived IgG responses in a similar population in west-
ern Thailand [13], this may account for the lack of a 
statistically significant increase in IgG level detected in 
volunteers with a current P. vivax infection. In addition, 
the pre-erythrocytic stage expression of this protein 
likely also contributes, as only new (and not relapsing) 
infections would likely generate new exposure to this 
antigen.
A higher IgG level was observed to nine of ten blood-
stage proteins in volunteers with a current P. vivax 
infection at the time of sampling. This difference was sta-
tistically significant despite the low number of infected 
volunteers (n = 22) and the low antigenic input of these 
asymptomatic infections. The greatest differences in 
mean IgG levels between individuals currently uninfected 
and those infected with P. vivax were observed for the 
proteins PVX_081550, P41, and RBP2cNB. Antibodies to 
both PVX_081550, or StAR-related lipid transfer protein, 
and P41 have recently been associated with protection 
from clinical malaria in PNG children [26]. RBP2cNB has 
also been associated with protection from clinical disease 
in PNG children; however, after accounting for the fact 
that antibodies to the various RBPs are co-acquired and 
correlated, only RBP1a and RBP2b remained significantly 
associated [25]. IgG levels to RBP2b were not assessed 
in the current study. Whilst the results suggest that cur-
rent asymptomatic P. vivax infections induce a boosting 
of the IgG response, at least at a community-wide level, 
the higher IgG levels could also reflect a higher risk of 
infection (and hence higher lifetime exposure) in these 
volunteers. Further analysis using samples from longi-
tudinal cohorts, including volunteers with symptomatic 
infections, will be required to determine whether these 
IgG antibodies are indeed associated with exposure or 
protection from clinical disease. Parasite clearance times 
were not determined for infected individuals in this 
cross-sectional survey.
As expected [35–39], IgG levels to most of the proteins 
were higher in adults (18  years and older) compared to 
children. The serocatalytic models indicated that either 
there was a reduction in transmission 15–30  years ago, 
or that during the ages 15–30 a difference in risk of expo-
sure exists. As mosquitoes in Thailand are known to bite 
outdoors, this fits with an increased risk in exposure to 
P. vivax in this age group who is likely working outdoors 
[3]. Two exceptions were found: IgG levels to both RBP2-
P2 and RBP1b were no different between the four defined 
age categories, nor did they correlate with age. Previ-
ous research also identified no association of IgG levels 
to RBP2-P2 with age in PNG [25], although this was not 
the case for RBP1b. This suggests that in western Thai-
land IgG antibodies to these two RBPs could be acquired 
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early in life, although this would be unexpected given 
the low transmission in this region. However, antibody 
responses to these two RBPs could be long lasting even in 
the absence of new infections. An alternative explanation 
is the existence of cross-reactive antibodies in this region 
to these protein constructs, which could generate a high 
level of non-specific antibodies. Using a multivariate lin-
ear regression model, the association with age reached 
a plateau in adults for most proteins. Age and current P. 
vivax infection status had the most significant influence 
on antibody levels in this study.
The use of antibody responses for identifying regions or 
hot spots of higher malaria transmission amongst a wider 
area of low transmission is gaining increasing interest 
[40]. All volunteers in this study lived within a limited 
area (3 km); however, spatial heterogeneity in the IgG lev-
els to a subset of the P. vivax proteins was still identified. 
For those proteins, IgG levels were significantly higher in 
individuals living closer to the Myanmar border and fur-
ther away from local health care facilities. Whilst travel 
to Myanmar is a known risk factor for malaria parasite 
infections in Thailand (Nguitragool et al. submitted), the 
volunteers in this village did not report sleeping outside 
their local village within the last month, and all had been 
living in Thailand for more than 2 months. Further details 
on their travel history within the past few years would 
be required to determine if they had been exposed to a 
greater risk of infection compared to other volunteers in 
the study. Overall, the results do support the use of anti-
body responses as tools to identify regions of ongoing 
malaria transmission: asymptomatic infections are asso-
ciated with increased IgG levels, and even a crude spatial 
separation can elicit a significant difference in this level. 
However, it is important to note that the impact of spatial 
location on IgG level was not as crucial as the influence 
of age and current P. vivax infections in this population, 
with most associations with spatial location lost in the 
multivariate model.
Conclusions
Here, IgG levels to 11 P. vivax proteins in over 500 indi-
viduals are reported. It is demonstrated that all proteins 
are recognized by a proportion of the volunteers, even in 
young children and those uninfected with P. vivax para-
sites. These proteins are also recognized in other endemic 
regions, such as Cambodia [23] and the Solomon Islands 
[26], and hence these responses are not specific to west-
ern Thailand. Asymptomatic P. vivax infections were 
associated with higher IgG levels to most proteins, 
despite the low density of such infections. Increased IgG 
levels were also associated with an increase in age for 
most proteins. Further investigation of such antibody lev-
els in low-transmission regions, such as Thailand, has the 
potential to provide valuable information for the devel-
opment and implementation of elimination tools such as 
surveillance markers and vaccines.
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